Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children.

BACKGROUND The clinical manifestations of inherited disorders of fatty acid oxidation vary according to the enzymatic defect. They may present as isolated cardiomyopathy, sudden death, progressive skeletal myopathy, or hepatic failure. Arrhythmia is an unusual presenting symptom of fatty acid oxidation deficiencies. METHODS AND RESULTS Over a period of 25 years, 107 patients were diagnosed with an inherited fatty acid oxidation disorder. Arrhythmia was the predominant presenting symptom in 24 cases. These 24 cases included 15 ventricular tachycardias, 4 atrial tachycardias, 4 sinus node dysfunctions with episodes of atrial tachycardia, 6 atrioventricular blocks, and 4 left bundle-branch blocks in newborn infants. Conduction disorders and atrial tachycardias were observed in patients with defects of long-chain fatty acid transport across the inner mitochondrial membrane (carnitine palmitoyl transferase type II deficiency and carnitine acylcarnitine translocase deficiency) and in patients with trifunctional protein deficiency. Ventricular tachycardias were observed in patients with any type of fatty acid oxidation deficiency. Arrhythmias were absent in patients with primary carnitine carrier, carnitine palmitoyl transferase I, and medium chain acyl coenzyme A dehydrogenase deficiencies. CONCLUSIONS The accumulation of arrhythmogenic intermediary metabolites of fatty acids, such as long-chain acylcarnitines, may be responsible for arrhythmias. Inborn errors of fatty acid oxidation should be considered in unexplained sudden death or near-miss in infants and in infants with conduction defects or ventricular tachycardia. Diagnosis can be easily ascertained by an acylcarnitine profile from blood spots on filter paper.

[1]  D. Bonnet,et al.  Fatty acid β-oxidation deficiency masquerading as fulminant myocarditis , 1998 .

[2]  T. Cowan,et al.  Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. , 1998, The Journal of pediatrics.

[3]  D. Bonnet,et al.  Tachycardies ventriculaires néonatales. , 1998 .

[4]  P. Rustin,et al.  Efficiency of metabolic screening in childhood cardiomyopathies. , 1998, European heart journal.

[5]  N. Gregersen,et al.  Fatty acid oxidation disorders as primary cause of sudden and unexpected death in infants and young children: an investigation performed on cultured fibroblasts from 79 children who died aged between 0-4 years. , 1997, Molecular pathology : MP.

[6]  R. Weingart,et al.  Modulation of cardiac gap junctions: the mode of action of arachidonic acid. , 1997, Journal of Molecular and Cellular Cardiology.

[7]  J. Horowitz,et al.  Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. , 1996, Biochemical pharmacology.

[8]  A. Leaf,et al.  Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. , 1996, European journal of pharmacology.

[9]  M. Bennett,et al.  Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. , 1995, Clinical chemistry.

[10]  C. Malloy,et al.  Direct Evidence That Perhexiline Modifies Myocardial Substrate Utilization from Fatty Acids to Lactate , 1995, Journal of cardiovascular pharmacology.

[11]  A. Legrand,et al.  Rapid Diagnosis of Long Chain and Medium Chain Fatty Acid Oxidation Disorders Using Lymphocytes , 1995, Annals of clinical biochemistry.

[12]  J. Saudubray,et al.  Inborn Metabolic Diseases: Diagnosis and Treatment , 1995 .

[13]  M. Arita,et al.  [Cellular electrophysiological basis of proarrhythmic and antiarrhythmic effects of ischemia-related lipid metabolites]. , 1993, Rinsho byori. The Japanese journal of clinical pathology.

[14]  S. Pande,et al.  Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts. , 1993, The Journal of clinical investigation.

[15]  M. Bacaner,et al.  Long-chain fatty acids activate calcium channels in ventricular myocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Valle,et al.  Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake , 1991, Annals of neurology.

[17]  R. Gilbert,et al.  Inherited metabolic diseases in the sudden infant death syndrome. , 1991, Archives of disease in childhood.

[18]  S. Pogwizd,et al.  Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. , 1991, Journal of molecular and cellular cardiology.

[19]  P. Rizzon,et al.  High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. , 1989, European heart journal.

[20]  P. Corr,et al.  Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. , 1989, The Journal of clinical investigation.

[21]  K. Gibson,et al.  Oxidation of Fatty Acids in Cultured Fibroblasts: a Model System for the Detection and Study of Defects in Oxidation , 1982, Pediatric Research.

[22]  I. Karl,et al.  Lipid transport in the human newborn. Palmitate and glycerol turnover and the contribution of glycerol to neonatal hepatic glucose output. , 1982, The Journal of clinical investigation.

[23]  M. Katcher,et al.  Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. , 1981, The New England journal of medicine.

[24]  S. Ruddy,et al.  Congenital Heart Block in Newborns of Mothers with Connective Tissue Disease , 1977, Circulation.

[25]  P. Ott Ventricular arrhythmias , 2000, Current treatment options in cardiovascular medicine.

[26]  R. Campbell,et al.  Paediatric cardiac arrhythmias , 1996 .